Moloney murine leukemia virus (M-MuLV) is capable of inducing promonocytic leukemia in 50% of adult BALB/c mice that have received peritoneal injections of pristane, but Friend MuLV strain 57 (F-MuLV) is nonleukemogenic under similar conditions. It was shown earlier that these differences could not be mapped to the U3 region of the virus long terminal repeat, indicating the probable influence of structural genes and/or R-U5 sequences. In this study, reciprocal chimeras containing exchanged structural genes and R-U5 sequences from these two closely related viruses were analyzed for differences in ability to induce disease. Results showed that two regions of F-MuLV, I-gag-PR and env, when substituted for those of M-MuLV were dramatically disease attenuating. The 5'-most region, which is widely distributed, overlaps with the 5' end of the env intron and includes the RNA packaging region, I, the entire gag coding region, and the viral protease coding region (PR) of pol. It was also found that reciprocal constructs having substitutions of both of these regions of M-MuLV in an F-MuLV background allowed full reestablishment of promonocytic leukemia. These leukemias were positive for c-myb rearrangements which are characteristic of M-MuLV-induced promonocytic leukemias. Neither region alone, however, was sufficient to produce disease with a greater incidence than 13%. Further studies demonstrated that the inability of viruses with I, gag, PR, or env sequences from F-MuLV to induce leukemia in this model system was not due to their inability to replicate in hematopoietic tissue, to integrate into the c-myb locus early on after infection in vivo, or to express gag-myb mRNA characteristic of M-MuLV-induced preleukemic cells and acute leukemia.
Moloney murine leukemia virus (M-MuLV)-induced myeloid leukemia (MML) can be induced with high incidence in adult BALB/c mice, but only when the mice are undergoing a chronic peritoneal inflammation as a result of pristane injection (26, 37, 38) . The disease manifests itself at the peritoneal inflammatory site at 3 to 4 months after virus inoculation and is characterized by proliferation of promonocytic leukemia cells. Analysis of leukemias has demonstrated that 100% of them have undergone insertional mutagenesis at the c-myb locus (reference 26 and unpublished data).
Since Friend MuLV (F-MuLV) is closely related to MMuLV but does not induce promonocytic leukemias in adult pristane-treated mice, we have had an ongoing interest in determining the genetic basis for the different in vivo responses of the viruses. In a previous study, we determined that the different abilities of F-and M-MuLVs to induce promonocytic disease could not be attributed to sequences in the U3 region of the long terminal repeat (LTR) (36) , even though other studies had shown that the U3 regions of F-MuLV and M-MuLV contain determinants for erythroid and lymphoid leukemia (5, 6, 17, 30) .
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outside of the U3 region in M-MuLV influence development of promonocytic leukemia in adult mice. Reciprocal chimeras between the two viruses were analyzed for disease induction and the ability to replicate in hematopoietic tissue of adult BALB/c mice. In addition, leukemias which developed in these mice were analyzed for virus integration and rearrangement of the c-myb gene. Our results show that two distinct regions, the T-gag-PR and env regions, contain the determinants that are responsible for the different abilities of F-MuLV and MMuLV to induce MML in adult BALB/c mice.
MATERIALS AND METHODS
Molecular constructions. Viral DNA chimeras of F-MuLV (22) and M-MuLV 8.2 (28) were prepared from plasmids containing permuted versions of MuLV genomic DNA bearing a single LTR. F-MuLV 57 DNA was cloned in the EcoRI site of either pUC19A (30) or Bluescript to obtain p57A and pBS/57, respectively. M-MuLV 8.2 was cloned in the HindIII site of pUC19B (30) , providing p8.2B. These constructs were used to prepare recombinant plasmids pFME/A, pFMP/B, and pFMU5G/A as previously described (23) . The designation A or B at the end of a plasmid name refers to pUC19A or pUC19B, respectively. pFMU5GE/A was prepared by ligating the 2.6-kb SphI-ClaI fragment of p8.2B containing mostly env sequences ( Fig. 1) (31) and assay of reverse transcriptase activity (16 
RESULTS
Attenuation of MML by substitution of distinct regions of F-MuLV. F-MuLV is nonleukemogenic for the first 6 months after virus inoculation in adult BALB/c mice. To determine which genetic regions of F-MuLV are unable to support disease, specific regions of the M-MuLV genome were replaced with analogous regions of F-MuLV, and the resulting chimeras were evaluated for infectivity and leukemogenicity. The viruses used in this study are depicted in Fig. 2 . The MFL virus, which has an U3 LTR derived from F-MuLV and its remaining genome from M-MuLV, was previously reported and is as leukemogenic as M-MuLV (36) . Chimeric viruses constructed for this study had F-MuLV substitutions in the env region (MFE), pol region (MFP), sequences encoding the gag nucleocapsid (NC) and protease (PR) (MFNCPR), the RNA encapsidation region (T) and sequences encoding the matrix (MA), ppl2, and capsid (CA) proteins of gag (MFTMACA), and R-U5 and the leader sequence including the splice donor site (MFU5SD). The approximate locations of restriction endonuclease sites used in the viruses for recombination are depicted in Fig. 1 . All of the viruses were able to replicate in hematopoietic tissues in vivo, as monitored by infectious center assays using bone marrow cells taken 2 to 4 weeks after virus infection. As shown in Table 1 , the average number of infectious centers for each virus was greater than 2,500 per 2 x 106 bone marrow cells. The leukemogenic potential of these viruses was determined by inoculating intravenously 5 x 105 PFU of virus into pristane-treated adult BALB/c mice, and mice were examined for up to 6 months after virus infection for evidence of promonocytic leukemia. The disease incidences shown in Fig. 2 and Table 1 for M-MuLV and MFL were previously reported (26, 36) and are presented here for comparison. It was found from this study that the env sequence from F-MuLV was attenuating, giving an MML incidence of only 8% (two tumors in 25 injected mice), compared with an incidence of 50% for M-MuLV ( Fig. 2 and Table 1 ). In addition, gag sequences from F-MuLV had an even more potent negative effect on disease induction, since two chimeric DNAs from leukemias induced by the chimeras were examined for rearrangements at the c-myb locus because this has been a characteristic of 100% of leukemias induced by MMuLV (26) . For each virus construct, the overall number of tumors that were positive for c-myb rearrangements per number tested is reported in Table 1 , and examples of the rearrangements are shown in Fig. 3 . DNAs depicted in Fig. 3 had rearrangements of a 4.2-kb EcoRI fragment, which is the most typical rearrangement observed in M-MuLV-induced promonocytic leukemias.
Establishment of promonocytic leukemia in F-MuLV by substitutions of sequences of M-MuLV. Our results indicated that T-gag-PR and env sequences of F-MuLV, when placed in the context of the M-MuLV genome, attenuate promonocytic disease in adult BALB/c mice, whereas the LTR and pol sequences do not. Reciprocal chimeras were prepared to determine the regions of M-MuLV capable of conferring MML-inducing capabilities in an F-MuLV background. The genetic structure of the viruses used in this experiment are depicted in Fig. 4 . F-MuLV as well as the chimeric viruses constructed for this study were tested for infectivity in hematopoietic tissue and were found to be positive ( Table 2 ). The incidence and latency of promonocytic disease for this set of viruses is presented in Table 2 , and the overall percentage of disease incidence is given in Fig. 4 leukemia after infection with FME, and it was shown to have no rearrangement at the c-myb locus (Fig. 5) . No leukemias were induced by FMP. Six leukemias were induced by FMU5G, all of which were positive for c-myb rearrangements (Table 2 and Fig. 5) that no chimeras with single regions of substitution could mimic the wild-type virus. We next tested the effect of substitution of the two regions of M-MuLV, T-gag-PR and env, which conferred partial MML-inducing ability, into an FMuLV context. The corresponding virus, FMU5GE (Fig. 4) , produced a very high incidence of disease (64%), and four of five FMU5GE-induced leukemias examined for c-myb rearrangement were positive (Table 2 and Fig. 5 ). This finding confirmed the results shown in Fig. 2 and Table 1 on attenuation of M-MuLV by F-MuLV sequences, which suggested that these two regions of F-MuLV located outside the LTR were entirely responsible for its lack of MML-inducing ability.
Insertional mutagenesis of c-myb after virus infection. Since no correlation was observed between the ability of F-MuLV, M-MuLV, or chimeric viruses to replicate in hematopoietic tissue and cause disease (Table 2) , we began to look for other potential blocks in the disease process of the non-MMLinducing viruses. Previous analysis of M-MuLV-induced tumors had indicated that the formation of gag-myb mRNA is required as a part of the activation mechanism of c-myb in M-MuLV-induced tumors and that a specific donor splice site is utilized in gag to produce this RNA (26) . In addition, we had previously demonstrated that in mice inoculated with MMuLV, gag-myb mRNA produced as a result of insertional mutagenesis of the c-myb locus could be detected in preleukemic mice by RT-PCR as early as 2 to 3 weeks after virus infection (21) . Since gag functions in proto-oncogene activation and gag is in part responsible for the nonpathogenic nature of F-MuLV, one explanation for the inability of viruses containing gag sequences from F-MuLV to cause disease might be their inability to support the formation of the gag-myb mRNA. Therefore, we examined bone marrow, spleen, and inflammatory granuloma tissue, caused by pristane injection, by RT-PCR for the presence of gag-myb fusion message. Total RNA was extracted from tissues obtained from mice infected for 4 to 8 weeks with M-MuLV, F-MuLV, or several chimeric viruses. The RNA was subjected to reverse transcription, and two rounds of amplification were performed with nested primers homologous to gag and myb. Products from the second round of amplification were separated on agarose gels, and Southern blots derived from these products were hybridized with oligonucleotide probes specific for three different gag-myb junctions. The JEX-3 and JEX-4 probes detected splice junctions of gag to myb, exons 3 and 4, respectively. These are the junctions found to be present in all M-MuLV-induced promonocytic leukemias examined so far. The results in Table  3 demonstrated that both F-MuLV-and M-MuLV-inoculated mice were positive for the leukemia-specific messenger. All of 12 F-MuLV-inoculated mice were positive in at least one tissue (this includes data from tissue samples taken both 4 and 8 weeks after virus infection). All of these mice were positive with the FJEX-4 probe and usually at multiple sites; in addition, three mice were positive with the FJEX-3 probe. Figure 6 depicts PCR products in F-MuLV-infected mice after hybridization with FJEX-4, which demonstrates the spliced mRNA product which is most commonly observed in MMuLV-induced leukemias. As shown in Table 3 , mice inocu- lated with a number of other chimeras, with and without F-MuLV-derived gag, were also strongly positive for gag-myb mRNA. A comparison of the tissue distribution of gag-mybpositive cells in F-MuLV-and M-MuLV-infected mice is presented in Table 4 . Since there were no tissues for which M-MuLV-infected mice were demonstrated to be more positive than F-MuLV-infected mice, it was concluded that a difference in tissue distribution of the leukemia-specific message is not likely to account for the difference in pathogenicity of the two viruses. DISCUSSION This study and one reported previously demonstrate that clearly distinct determinants of F-MuLV are responsible for its lack of induction of MML in adult-inoculated animals and T lymphomas in newborn-inoculated animals. Whereas it had been shown, using M-MuLV/F-MuLV chimeras, that the U3 region of M-MuLV is necessary for lymphoid disease (5, 17) , our previous studies showed that sequences independent of the LTR of M-MuLV are necessary for promonocytic leukemia. In fact, reciprocal M-MuLV/F-MuLV chimeric viruses that ex- (36) . The results of the present study further define the determinants of M-MuLV specifically required for inducing promonocytic leukemia in adult BALB/c mice. These are found in two separate regions, T-gag-PR and env. When M-MuLV substitutions including both of these regions were present in a backbone of F-MuLV, it was possible to reestablish a high incidence of induction of promonocytic leukemia by F-MuLV. When individual M-MuLV T-gag-PR or env regions were substituted for analogous regions of F-MuLV, however, wild-type pathogenicity was never obtained; individual substitution of either of these regions did not produce a disease incidence that exceeded 13%.
When our present studies implicated an important role of M-MuLV gag in the development of promonocytic leukemias involving c-myb, we envisioned that this region might be important in the alternative splicing from gag to myb observed in M-MuLV-induced promonocytic leukemias (21, 26) . Furthermore, we proposed that F-MuLV might be defective in promoting this splicing. However, when we examined FMuLV-infected mice early on for the presence of gag-myb mRNA, we were able to detect the fusion message with at least equal frequency as we detected this mRNA in M-MuLVinfected mice. Nevertheless, it remains possible that in FMuLV-infected animals, gag-myb RNA products are not effective in producing a functionally active gag-myb protein or that the alternatively spliced RNA is not expressed in the specific myeloid or precursor target cells that are required for leukemogenesis.
Since we found that envelope influences the lack of induction of MML by F-MuLV, it is possible that differences in Env can affect cell distribution in vivo. Several studies have de- (10, 11 ). An alternative explanation for env influence on leukemia induction might be that distinct antigenic properties of the F-MuLV and M-MuLV env gene products stimulate the immune response differently. We are currently evaluating the pathogenicity of F-MuLV, M-MuLV, and chimeras in immunocompromised mice to address this point.
Enhancer sequences have been important in determining disease specificity in several leukemogenic models (3, 4, 6, 7, 12, 13, 33, 34, 39) . Since enhancer sequences are not always confined to the LTR of retroviruses (1, 35) , we must consider the possibility that there are differences between F-MuLV and M-MuLV in enhancer-like sequences in gag and/or env that could account for differential expression of the viruses in cellular subsets.
Using a different model of pathogenesis, we showed previously that F-MuLV inoculated into newborn mice induces severe hemolytic anemia (EHA) independently of leukemogenic ability and M-MuLV is ineffective in inducing EHA (23, 30, 32) . Interestingly, in both the EHA model and that described here, determinants dispersed along the T-gag-PR region play a major role in the difference in pathogenesis observed between F-MuLV and M-MuLV (reference 23 and this study). The facts that myb activation involves alternative splicing from this region and induction of EHA depends on efficient formation of the spliced env subgenomic message raise the interesting possibility that the opposite virulence of FMuLV and M-MuLV in the MML and EHA models could be due to cell-specific regulation of splicing influenced by the T-gag-PR region. In favor of this view is the description of a negative regulatory sequence for splicing in the capsid encoding region of Rous sarcoma virus (20) . Therefore, the T-gag-PR region of M-MuLV is implicated in both enhancement of MML and attenuation of EHA, whereas the same region of F-MuLV has the opposite influence. Further studies on these models are likely to provide more insight on the precise mechanisms by which these sequences influence pathogenesis in the promonocytic and erythroid models.
